Centessa Pharmaceuticals Director Reports Share Disposition Following Eli Lilly Acquisition

This Form 4 filing reports that Centessa Pharmaceuticals plc director Francesco De Rubertis disposed of all his shares in the company following its acquisition by Eli Lilly and Company. On June 24, 2026, Eli Lilly completed the acquisition of Centessa through a scheme of arrangement, with shareholders receiving $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. De Rubertis disposed of a total of 19,999,157 ordinary shares across six different Medicxi investment funds where he has indirect ownership interests. The shares were transferred automatically at the effective time of the acquisition without any action by the reporting person. The filing includes disclaimers that De Rubertis does not claim beneficial ownership of the shares held by the Medicxi funds except to the extent of his pecuniary interest.